Hopes and concerns regarding the implementation of expanded access protocols in amyotrophic lateral sclerosis

Affiliations

¹ Department of Neurology, Columbia University Irving Medical Center, New York, New York, USA.
² Department of Neurology, Penn State College of Medicine, Hershey, Pennsylvania, USA.

Editorial

Ikjae Lee et al. Muscle Nerve. 2023 Jun.

. 2023 Jun;67(6):433-435.

doi: 10.1002/mus.27828. Epub 2023 Apr 10.

¹ Department of Neurology, Columbia University Irving Medical Center, New York, New York, USA.
² Department of Neurology, Penn State College of Medicine, Hershey, Pennsylvania, USA.

No abstract available

Keywords: EAP; amyotrophic lateral sclerosis; compassionate use; expanded access; expanded access protocol.

Comment on

Expanded access protocol (EAP) program for access to investigational products for amyotrophic lateral sclerosis (ALS).
Yerton M, Winter A, Gelevski D, Addy G, Kostov A, Lieberman C, Weber H, Doyle M, Kane G, Cohen C, Parikh N, Burke KM, Rohrer M, Stirrat T, Bruno M, Hochman A, Luppino S, Scalia J, D'Agostino D, Sinani E, Yu H, Drake K, Hagar J, Sherman AV, Babu S, Berry JD, Cudkowicz ME, Paganoni S. Yerton M, et al. Muscle Nerve. 2023 Jun;67(6):456-463. doi: 10.1002/mus.27819. Epub 2023 Apr 5. Muscle Nerve. 2023. PMID: 36929648

1. Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole study group. N Engl J Med. 1994;330(9):585-591.
1. Writing G, Edaravone ALSSG. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16(7):505-512.
1. Paganoni S, Macklin EA, Hendrix S, et al. Trial of sodium Phenylbutyrate-Taurursodiol for amyotrophic lateral sclerosis. N Engl J Med. 2020;383(10):919-930.
1. Yerton M, Winter A, Gelevski D, et al. Expanded access protocol (EAP) program for access to investigational products for amyotrophic lateral sclerosis (ALS). Muscle Nerve. 2023;67(6):456-463. doi:10.1002/mus.27819.
1. FDA Releases Action Plan for Rare Neurodegenerative Diseases Including ALS, U.S. FOOD & DRUG ADMINSTRATION website, https://www.fda.gov/news-events/press-announcements/fda-releases-action-..., updated June 23, 2022. Accessed March 28, 2023.